Aclaris Therapeutics, Inc. (ACRS)Healthcare | Biotechnology | Wayne, United States | NasdaqGS
5.43 USD
-0.07
(-1.273%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:49 a.m. EDT
The immediate outlook is driven by a classic biotech binary event structure. While the company recently posted positive interim results for its ATI-052 trial, the balance sheet tells a cautionary tale: negative free cash flow and a lack of profitability mean the stock relies entirely on future financing or a blockbuster readout to survive. The market has priced in a struggle, evidenced by the 92% decline over the last nine years, though the recent price action suggests investors are starting to price in a potential turnaround. However, the lack of a dividend and the heavy reliance on speculative call buying at distant strikes indicates that the current rally is fragile and dependent on a specific clinical milestone rather than sustainable earnings power. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.071327 |
| MSTL | 0.073242 |
| AutoETS | 0.095754 |
| AutoARIMA | 0.095758 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.527 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.382 |
| Revenue per Share | 0.067 |
| Market Cap | 758,373,760 |
| Forward P/E | -6.55 |
| Beta | 0.77 |
| Website | https://www.aclaristx.com |
As of July 11, 2026, 4:49 a.m. EDT: Speculators are positioning for a volatile recovery rather than a steady grind. Call open interest is heavily skewed toward out-of-the-money strikes (7.0 and 8.0) for later expirations, suggesting bets on a significant gap-up event. Conversely, put open interest is concentrated deep in-the-money (3.0 and 4.0) for the near term, indicating a hedge against a drop back to the lows. The massive volume spike in July 2027 calls at the 7.0 strike relative to existing open interest signals fresh speculative capital entering the trade expecting a major catalyst.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.618421 |
| Address1 | 701 Lee Road |
| Address2 | Suite 103 |
| All Time High | 33.88 |
| All Time Low | 0.59 |
| Ask | 6.87 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,772,090 |
| Average Daily Volume3 Month | 1,556,606 |
| Average Volume | 1,556,606 |
| Average Volume10Days | 1,772,090 |
| Beta | 0.769 |
| Bid | 3.91 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.029 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.43 |
| Current Ratio | 4.027 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.648 |
| Day Low | 5.35 |
| Debt To Equity | 1.382 |
| Display Name | Aclaris Therapeutics |
| Earnings Call Timestamp End | 1,715,115,600 |
| Earnings Call Timestamp Start | 1,715,115,600 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -78,469,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.471 |
| Enterprise To Revenue | 79.445 |
| Enterprise Value | 664,719,232 |
| Eps Current Year | -0.655 |
| Eps Forward | -0.82889 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.762 |
| Fifty Day Average Change | 0.66799974 |
| Fifty Day Average Change Percent | 0.14027713 |
| Fifty Two Week Change Percent | 261.8421 |
| Fifty Two Week High | 5.85 |
| Fifty Two Week High Change | -0.42000008 |
| Fifty Two Week High Change Percent | -0.07179488 |
| Fifty Two Week Low | 1.46 |
| Fifty Two Week Low Change | 3.9699998 |
| Fifty Two Week Low Change Percent | 2.719178 |
| Fifty Two Week Range | 1.46 - 5.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,444,138,200,000 |
| Float Shares | 113,135,961 |
| Forward Eps | -0.82889 |
| Forward P E | -6.550929 |
| Free Cashflow | -32,210,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -55,907,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.022850001 |
| Held Percent Institutions | 0.79627 |
| Implied Shares Outstanding | 139,663,680 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. |
| Long Name | Aclaris Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 758,373,760 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_216879819 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -69,662,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 767,451,921 |
| Number Of Analyst Opinions | 10 |
| Open | 5.648 |
| Operating Cashflow | -52,205,000 |
| Operating Margins | -11.118239 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 484 324 7933 |
| Previous Close | 5.5 |
| Price Eps Current Year | -8.290076 |
| Price Hint | 2 |
| Price To Book | 5.2769675 |
| Price To Sales Trailing12 Months | 90.63867 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.027 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.07000017 |
| Regular Market Change Percent | -1.2727305 |
| Regular Market Day High | 5.648 |
| Regular Market Day Low | 5.35 |
| Regular Market Day Range | 5.35 - 5.648 |
| Regular Market Open | 5.648 |
| Regular Market Previous Close | 5.5 |
| Regular Market Price | 5.43 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 832,207 |
| Return On Assets | -0.24723 |
| Return On Equity | -0.48424 |
| Revenue Growth | 0.372 |
| Revenue Per Share | 0.067 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 139,663,680 |
| Shares Percent Shares Out | 0.0817 |
| Shares Short | 11,404,860 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,075,151 |
| Short Name | Aclaris Therapeutics, Inc. |
| Short Percent Of Float | 0.0934 |
| Short Ratio | 5.76 |
| Source Interval | 15 |
| State | PA |
| Symbol | ACRS |
| Target High Price | 16.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 105,416,000 |
| Total Cash Per Share | 0.755 |
| Total Debt | 1,985,000 |
| Total Revenue | 8,367,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.4894 |
| Two Hundred Day Average Change | 1.9405999 |
| Two Hundred Day Average Change Percent | 0.55614144 |
| Type Disp | Equity |
| Volume | 832,207 |
| Website | https://www.aclaristx.com |
| Zip | 19,087 |